Back to Journals » OncoTargets and Therapy » Volume 10

Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia

Authors Khan M, Gibbons JL, Ferrajoli A

Received 4 November 2016

Accepted for publication 23 December 2016

Published 29 March 2017 Volume 2017:10 Pages 1909—1914

DOI https://doi.org/10.2147/OTT.S98689

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Manfred Beleut

Peer reviewer comments 2

Editor who approved publication: Dr William Cho

Maliha Khan, Jamie L Gibbons, Alessandra Ferrajoli

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Abstract: Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the adult population. Current efforts are focused on better understanding the intricate pathophysiology of the disease to develop successful targeted therapies. Ibrutinib is emerging as an important agent in this new age of targeted treatment for CLL. As a Bruton’s tyrosine kinase inhibitor, it blocks the signaling pathway that malignant B-lymphocytes need for growth and maturation. Ibrutinib’s role in therapy was further expanded recently when the US Food and Drug Administration approved its use in both frontline and salvage treatment for patients with CLL. This review assesses the effectiveness of ibrutinib in the frontline setting, its efficacy in various types of patients with CLL, and its safety and tolerability.

Keywords: ibrutinib, CLL, frontline therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]